Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced Melanoma

Cartun Z, Kunz WG, Heinzerling L, Tomsitz D, Guertler A, Westphalen CB, Ricke J, Weir W, Unterrainer M, Mehrens D (2022)

Publication Type: Journal article

Publication year: 2022

Journal

JAMA Dermatology American Medical Association

DOI: 10.1001/jamadermatol.2022.4556

Abstract

IMPORTANCE Combination immunotherapy with nivolumab and ipilimumab has markedly improved outcomes for patients with advanced melanoma. However, these therapies pose a considerable financial burden to both patients and the health care system. The ADAPT-IT trial demonstrated comparable progression-free and overall survival for patients with response-adapted ipilimumab discontinuation compared with standard of care (SOC).

Authors with CRIS profile

Lucie Heinzerling Department of Dermatology

Involved external institutions

Ludwig-Maximilians-Universität (LMU) DE Germany (DE) University of Massachusetts Amherst (UMass) US United States (USA) (US)

How to cite

APA:

Cartun, Z., Kunz, W.G., Heinzerling, L., Tomsitz, D., Guertler, A., Westphalen, C.B.,... Mehrens, D. (2022). Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced Melanoma. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2022.4556

MLA:

Cartun, Zachary, et al. "Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced Melanoma." JAMA Dermatology (2022).

BibTeX: Download